65,437 trials
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Primary: Change From Baseline to Week 16 in Sino-Nasal Outcome Test (SNOT) 22 Total Score — -18.1; -18.3 score on a scale — p=0.9499
Prostate Cancer · Prostate Adenocarcinoma
Primary: Number of Participants With Biopsy Failure — 0; 2 Participants
Hemophilia B
Primary: Percentage of Participants Who Developed Factor IX (FIX) Inhibitors — 0 Percentage of participants
Chronic Kidney Disease
Primary: FGF23 — .047; -.003; .193; .138 pg/ml
Anemia
Primary: Characterization of Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Events
Traumatic Brain Injury (TBI) · Healthy
Primary: Receptor Binding (Vt) — 2.53; 2.21; 3.21; 3.22 mL/cm^3
Irritable Bowel Syndrome
Primary: Number of Irritable Bowel Syndrome (IBS) With Predominantly Diarrhea (IBS-D) Participants Who Were Abdominal Pain Intensity (API) Weekly Responders at Week 12 — 27; 27…
General Surgery
Primary: Analgesic Affect of Tramadol After Major Abdominal Surgery — 7; 5; 5; 3 Score on a scale
Multiple Myeloma
Primary: Average Absorbed Radiation Dose Estimates for Normal Tissues for Phase I Participants — 0.49 mSv/MBq
Asthma
Primary: Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type — 109; 105; 111; 102 Participants
PTSD
Primary: Change From Baseline to Visit 19 in CAPS-5 Total Severity Scores — -30.49 score on a scale
Endometrial Cancer
Primary: Change in Steps in Endometrial Cancer Survivors During 12 Week Intervention — 1037; 309 Change in steps
Diffuse Large B-Cell Lymphoma Refractory · Diffuse Large B-cell Lymphoma Recurrent
Primary: Overall Response Rate (ORR) — 48.3 percentage of participants
Aggressive Periodontitis
Primary: Change in Probing Depth — 3.88; 3.74; 3.38; 3.26 milimeters — p=<0.05
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Safety of NKTR-214 as Evaluated by Incidence of Drug-related Adverse Events (AEs) — 2; 8; 2; 1 events